# A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

> **NCT07130383** · PHASE2 · RECRUITING · sponsor: **Minghui Pharmaceutical (Hangzhou) Ltd** · enrollment: 210 (estimated)

## Conditions studied

- Advanced Breast Cancer
- Advanced Malignant Solid Tumor

## Interventions

- **DRUG:** MHB036C for Injection
- **DRUG:** MHB039A for Injection

## Key facts

- **NCT ID:** NCT07130383
- **Lead sponsor:** Minghui Pharmaceutical (Hangzhou) Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-30
- **Primary completion:** 2029-08
- **Final completion:** 2031-08
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07130383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07130383, "A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07130383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*